Close Menu

NEW YORK (GenomeWeb) – OncoCyte reported after the close of the market on Tuesday that its third quarter net loss more than doubled amid higher operating expenses.

The company also disclosed a delay in the planned commercial launch of its first product, the liquid biopsy lung cancer diagnostic DetermaVu, due to technical issues during a clinical validation study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.